BPC-157 vs KPV
BPC-157 (Synthetic pentadecapeptide) and KPV (Alpha-MSH-derived tripeptide fragment) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | BPC-157 | KPV |
|---|---|---|
| Compound class | Synthetic pentadecapeptide | Alpha-MSH-derived tripeptide fragment |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | 15 amino acids | 3 amino acids |
| Molecular weight | 1419.5 Da | 342.43 g/mol |
| Half-life | <30 minutes (elimination, reported in rats/dogs) | Not documented |
| Origin | BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research. | KPV is a synthetic tripeptide corresponding to the C-terminal three amino acids (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring melanocortin peptide. It is studied as a fragment that retains some anti-inflammatory properties of the parent hormone. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How BPC-157 works
In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.
How KPV works
KPV is reported in preclinical studies to exert anti-inflammatory effects, and research has explored both melanocortin-receptor-dependent signaling and intracellular actions independent of classic MSH pigmentation activity. It has been studied for downregulation of pro-inflammatory signaling such as NF-kB-associated pathways in cell and animal models of colitis. These findings derive from in-vitro and rodent research.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
BPC-157
KPV
What sets each apart
BPC-157
Unlike copper-binding cosmetic tripeptides or the actin-modulating TB-500, BPC-157 is a longer synthetic peptide studied primarily for connective-tissue and gastrointestinal repair endpoints in animals.
KPV
KPV is distinguished by its melanocortin-pathway anti-inflammatory focus, in contrast to the antimicrobial LL-37 or the tissue-repair emphasis of BPC-157 and TB-500.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is BPC-157 and what class of peptide is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is studied in the research literature as a cytoprotective and tissue-repair agent, not as an approved drug. It has no established endogenous receptor and its mechanisms are still under active investigation.
What is BPC-157 studied for in the research literature?
In animal models, BPC-157 has been researched in the context of tendon, ligament, muscle, and bone healing, gastrointestinal mucosal protection, and angiogenesis. Much of the work implicates nitric oxide pathways and upregulation of growth-factor and angiogenic signaling. To date these findings are almost entirely preclinical, and no human clinical efficacy has been established.
Why is BPC-157's short half-life not reflected in dosing frequency?
Pharmacokinetic work in rats and dogs reports an elimination half-life under about 30 minutes, yet most rodent studies use once-daily dosing. This is often described as a PK/PD disconnect: the downstream biological effects the peptide triggers persist well beyond the peptide's own residence time. Researchers therefore design protocols around effect duration rather than plasma half-life.
What is KPV?
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains much of the parent hormone's anti-inflammatory activity while lacking its pigment-stimulating (melanocortin) effects. It is studied as a small anti-inflammatory peptide rather than as an approved therapeutic.
What is KPV studied for?
Preclinical research examines KPV for anti-inflammatory effects, particularly in models of intestinal inflammation and colitis, as well as skin inflammation. It is reported to enter cells and inhibit NF-kB signaling and pro-inflammatory cytokine production, and it can be transported into intestinal cells via the PepT1 transporter. No human clinical trials have confirmed these effects.
How does KPV produce anti-inflammatory effects without affecting pigmentation?
KPV corresponds only to the C-terminal tripeptide of alpha-MSH, so it preserves the anti-inflammatory activity associated with that region while omitting the sequence needed to activate melanocortin receptors that drive pigmentation. Mechanistically it is described as acting intracellularly on the NF-kB pathway, including inhibition of IkB kinase.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.